← Sobeck. · a take
On closed windows that weren't

The Deaf-Born Kids Who Heard — and the Part of the Story With No Press Release

*The OTOF therapy is being covered as a hearing story; the radical finding is neurological, the honest test is GJB2, and the unanswered question is the price.*

The occasion: gene therapy has restored hearing in children born deaf from OTOF mutations, and it's now FDA-approved — the first gene therapy for congenital deafness. CHOP's treatment page and trial results out of Harvard describe children who had never heard a sound now responding to it, with results holding over years. The coverage reads as a hearing story. It isn't, mostly. It's a neuroscience story wearing a hearing aid.

Here's why OTOF worked, at the cellular level. The therapy's target is a delivery problem, not a death sentence: the hair cells of the inner ear are present and structurally intact, but one protein they need to do their job — otoferlin — is missing. Gene therapy's whole trick is handing the cell the recipe it lacks. Intact machinery, absent part, install the part. That's the best case a genetic therapy can face, and OTOF is nearly the best case in the entire domain.

The quietly radical finding is one level up, in the cortex. The dogma says there are critical periods — windows in early development when the auditory cortex must receive input or it never learns to process sound; miss the window and the capacity is gone. What these children show is cortex that had never heard a sound wiring itself to speech once input finally arrived. That reframes some "closed windows" as waiting rooms: not capacities that expired, but capacities that sat there, unstimulated, still ready. And that reframe doesn't stop at hearing. Every developmental neuroscience claim built on "too late now" inherits a new burden of proof.

Now the part the coverage skips. The next likely target is GJB2, and it's a different disease in the way that matters: there, the problem is hair cells that die, not hair cells that idle. You can hand a living cell a missing protein. You can't hand a dead one anything. OTOF was the friendly exam; GJB2 is where the breakthrough narrative either generalizes or reveals itself to have been a best-case story all along. The honest coverage would say this explicitly instead of letting one therapy's success imply a category's.

And then the part with no press release at all. Weeks post-approval, there's no public price, while the sponsor sits in the $850,000–$2.2M tradition that gene therapies have priced themselves into. Congenital OTOF deafness is rare; the affected population is small; and the gene-therapy pricing model has historically treated small populations as justification for large numbers. A therapy that works, for babies, that most affected families never touch, is not a milestone — it's a demo. The science cleared its hurdles. The access question is the one still standing in the waiting room.

← all takes